merck & co. - Search News

News

Merck lowers profit Outlook

Merck Expects $200 Million Hit From Current US Tariffs

Merck & Co. said it expects to lose $200 million to already-announced tariffs in 2025 amid a roiling trade war between the US and China.

BioPharma Dive · 12h

Merck takes $200M tariff hit, trimming its gross profits

The drugmaker absorbed additional tariff-related costs in the first quarter, but has taken steps to lower the financial impact it’ll have for the rest of the year and beyond.

CNBC on MSN · 13h

Merck lowers profit outlook, partly due to $200 million expected tariff hit

Merck said the expected tariff charge primarily reflects levies between the U.S. and China, but does not account for Trump’s planned pharmaceutical tariffs.

Merck KGaA, SpringWorks and The Wall Street Journal

Reuters on MSN · 8h

Germany's Merck nears deal for SpringWorks, source says

Germany's Merck KGaA is nearing a deal for SpringWorks Therapeutics, a source close to the deal said on Thursday. Shares of SpringWorks rose 9.25% to $45.02. The Wall Street Journal, which first reported of the matter,

Bloomberg on MSN · 7h

Merck KGaA Nears Deal to Buy SpringWorks Therapeutics

Merck KGaA is nearing a deal to acquire SpringWorks Therapeutics Inc., people familiar with the matter said. An announcement may come as soon as Monday, the people said, asking not to be identified discussing confidential information.

Business Insider · 9h

Merck KGaA near $47 per share deal to buy SpringWorks Therapeutics, WSJ says

Germany’s Merck KGaA (MKGAY), which had confirmed in February it was in advanced talks to buy SpringWorks Therapeutics (SWTX), is nearing a

16h

MRK Earnings: Merck & Company Fears $200M Tariff Hit but Pet Drugs Give Bite to Q1 Sales

Pharmaceuticals giant Merck & Company (MRK) has cut its full-year profit forecasts fearing a $200 million hit from President ...

Fierce Pharma10h

Halozyme sues Merck over subcutaneous Keytruda as licensing talks fall through

Halozyme is not holding back against Merck & Co. in the companies' injectable Keytruda patent dispute, having now escalated a ...

Schaeffer's Investment Research14h

2 Blue-Chip Stocks Brushing Off Earnings Beats

Merck & Co (MRK) and Procter & Gamble (PG) are lower despite beating earnings expectations after lowering their guidance ...

Merck & Co.: Pipeline Resilience To Unlock Value

Merck is growing pharma sales and expanding margins, led by strong KEYTRUDA performance and cost discipline. Read more about ...

18h

Merck: Q1 Earnings Snapshot

On a per-share basis, the Rahway, New Jersey-based company said it had profit of $2.01. Earnings, adjusted for one-time gains and costs, came to $2.22 per share. The results exceeded Wall Street ...

11h

Merck warns of big tariff hit, Hasbro soars, Comcast sinks

Julie Hyman provides an overview of the top stories of the trading day in just 60 seconds on Yahoo Finance's Market Minute. Merck & Company (MRK) warns investors that it expects a $200 million hit ...

Fierce Pharma13h

Merck ‘willing to work’ with Trump administration on price gap between US, international medicines

With potential tariffs and other drug pricing policies on the horizon, the industry is navigating uncertain waters. | The ...

16h

Merck Faces Lawsuit to Block Launch of Easier-to-Use Keytruda

A biotech company is suing to block Merck & Co. from launching an easier-to-use version of its blockbuster cancer treatment ...

Results that may be inaccessible to you are currently showing.

Hide inaccessible results